
Publications

Safety and tolerability of Miltuximab[®] - a first in human study in patients with advanced solid cancers, Dhanusha Sabanathan, Douglas H. Campbell, Vicki M. Velonas, Sandra Wissmueller, Hubert Mazure, Marko Trifunovic, Pirooz Poursoltan, Kevin Ho Shon, Tiffany R. Mackay, Maria E. Lund, Yanling Lu, Paul J. Roach, Dale L. Bailey, Bradley J. Walsh, David Gillatt, Howard Gurney. Under review at EJNMMI Research.

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells, Maria E. Lund, Christopher B. Howard, Kristofer J. Thurecht, Douglas H. Campbell, Stephen M. Mahler, Bradley J. Walsh. Under revision at BMC Cancer.

The feasibility of Miltuximab[®]-IRDye700DX-mediated photoimmunotherapy of solid tumors, Dmitry M. Polikarpov, Douglas H. Campbell, Maria E. Lund, Yanling Lu, Yiqing Lu, Jiehua Wu, Bradley J. Walsh, Andrei V. Zvyagin, David A. Gillatt. Under revision at Photodiagnosis and Photodynamic Therapy.

RetroSPECT – Gallium-67 as a Theranostic Imaging Agent, Dale L. Bailey, Dhanusha Sabanathan, Alireza Aslani, Douglas H. Campbell, Bradley J. Walsh, Nigel A. Lengkeek. Submitted to Asia Oceania Journal of Nuclear Medicine and Biology.

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab[®]-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery, Dmitry M. Polikarpov, Douglas H. Campbell, Lucinda S. McRobb, Jiehua Wu, Maria E. Lund, Yanling Lu, Sergey M. Deyev, Andrew S. Davidson, Bradley J. Walsh, Andrei V. Zvyagin and David A. Gillatt. Cancers 2020, 12, 984; <http://doi.org/10.3390/cancers12040984>

Targeted beta therapy of prostate cancer with ¹⁷⁷Lu-labelled Miltuximab[®] antibody against glypican-1 (GPC-1), Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson and Pamela J. Russell. Yeh et al. EJNMMI Research (2020) 10:46; <https://doi.org/10.1186/s13550-020-00637-x>

The Role of Glypican-1 in the Tumour Microenvironment, Maria E. Lund, Douglas H. Campbell and Bradley J. Walsh. Springer Nature Switzerland AG 2020 A. Birbrair (ed.), Tumor Microenvironment, Advances in Experimental Medicine and Biology 1245; https://doi.org/10.1007/978-3-030-40146-7_8

Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells, Dmitry Polikarpov, Liuen Liang, Andrew Care, Anwar Sunna, Douglas Campbell, Bradley Walsh, Irina Balalaeva, Andrei Zvyagin, David Gillatt and Evgenii Guryev. *Biomolecules* 2019, 9, 820; <https://doi.org/10.3390/biom9120820>

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker, Rachel A. Levin, Maria E. Lund, Quach Truong, Angela Wu, Neal D. Shore, Daniel R. Saltzstein, Raoul S. Concepcion, Thomas A. Paivanas, Arletta van Breda, Jennifer Beebe-Dimmer, Julie J. Ruterbusch, Sandra Wissmueller, Douglas H. Campbell and Bradley J. Walsh. *Oncotarget*. 2018; 9(32): 22359–22367; <https://doi.org/10.18632/oncotarget.25009>

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer, Douglas H. Campbell, Maria E. Lund, Aline L. Nocon, Paul J. Cozzi, Mark Frydenberg, Paul De Souza, Belinda Schiller, Jennifer L. Beebe-Dimmer, Julie J. Ruterbusch, Bradley J. Walsh. *PLoS ONE* 13(4):e0196017; <https://doi.org/10.1371/journal.pone.0196017>

Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization, Quach Truong, Irene O. Justiniano, Aline L. Nocon, Julie T. Soon, Sandra Wissmueller, Douglas H. Campbell and Bradley J. Walsh. *J Cancer* 2016; 7(8):1002-1009; <https://doi.org/10.7150/jca.14645>